JP5635226B2 - 毛乳頭細胞増殖促進剤 - Google Patents
毛乳頭細胞増殖促進剤 Download PDFInfo
- Publication number
- JP5635226B2 JP5635226B2 JP2007555917A JP2007555917A JP5635226B2 JP 5635226 B2 JP5635226 B2 JP 5635226B2 JP 2007555917 A JP2007555917 A JP 2007555917A JP 2007555917 A JP2007555917 A JP 2007555917A JP 5635226 B2 JP5635226 B2 JP 5635226B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- growth
- glucosyl
- ascorbic acid
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004209 hair Anatomy 0.000 title claims description 191
- 230000010261 cell growth Effects 0.000 title description 24
- 239000007952 growth promoter Substances 0.000 title description 21
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 68
- 230000012010 growth Effects 0.000 claims description 44
- 210000004761 scalp Anatomy 0.000 claims description 31
- 238000002054 transplantation Methods 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000002513 implantation Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 3
- -1 glucosyl rutin Chemical compound 0.000 description 91
- 230000000694 effects Effects 0.000 description 77
- 210000004027 cell Anatomy 0.000 description 76
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 70
- 230000002500 effect on skin Effects 0.000 description 66
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 61
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 58
- 230000003779 hair growth Effects 0.000 description 56
- 230000004663 cell proliferation Effects 0.000 description 55
- 235000019192 riboflavin Nutrition 0.000 description 52
- 239000002151 riboflavin Substances 0.000 description 52
- 230000001737 promoting effect Effects 0.000 description 49
- 235000005493 rutin Nutrition 0.000 description 49
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 47
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 47
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 47
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 47
- 229960004555 rutoside Drugs 0.000 description 47
- 229940108690 glucosyl hesperidin Drugs 0.000 description 45
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 42
- 229960002477 riboflavin Drugs 0.000 description 42
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 35
- 239000003504 photosensitizing agent Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 31
- 235000000069 L-ascorbic acid Nutrition 0.000 description 29
- 230000035755 proliferation Effects 0.000 description 28
- 238000000034 method Methods 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 24
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 23
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 23
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 23
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 23
- 229940025878 hesperidin Drugs 0.000 description 23
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 23
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 23
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 201000004384 Alopecia Diseases 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 229960005070 ascorbic acid Drugs 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 230000003676 hair loss Effects 0.000 description 19
- 208000024963 hair loss Diseases 0.000 description 19
- 230000000284 resting effect Effects 0.000 description 19
- 239000002211 L-ascorbic acid Substances 0.000 description 18
- 230000009471 action Effects 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 150000001720 carbohydrates Chemical class 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229930003935 flavonoid Natural products 0.000 description 15
- 150000002215 flavonoids Chemical class 0.000 description 15
- 235000017173 flavonoids Nutrition 0.000 description 15
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 15
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 14
- 150000000996 L-ascorbic acids Chemical class 0.000 description 14
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 230000031774 hair cycle Effects 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- NIFXVRWMHZPIFE-KCLHJWPFSA-N cyclobis-(1->6)-alpha-nigerosyl Chemical compound O([C@H]1O[C@@H]([C@H]([C@H](O[C@H]2O[C@@H]([C@H]([C@H](O)[C@H]2O)O)CO[C@H]2O[C@H](CO)[C@@H](O)[C@@H]([C@H]2O)O2)[C@H]1O)O)CO)C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2O1 NIFXVRWMHZPIFE-KCLHJWPFSA-N 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 229940052490 naringin Drugs 0.000 description 13
- 229930019673 naringin Natural products 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000000845 maltitol Substances 0.000 description 10
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 10
- 235000010449 maltitol Nutrition 0.000 description 10
- 229940035436 maltitol Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 150000003287 riboflavins Chemical class 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 150000008163 sugars Chemical class 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
- 239000004359 castor oil Substances 0.000 description 7
- 235000019438 castor oil Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 150000002216 flavonol derivatives Chemical class 0.000 description 3
- 235000011957 flavonols Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 229940097275 indigo Drugs 0.000 description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 3
- 230000003273 male-pattern hair loss Effects 0.000 description 3
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000006098 transglycosylation Effects 0.000 description 3
- 238000005918 transglycosylation reaction Methods 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 2
- FEYNAYMVKUTMFN-UHFFFAOYSA-N 5-bromo-n-[2-(1-ethyl-6-methylpyridin-1-ium-2-yl)ethenyl]pyridin-2-amine;iodide Chemical compound [I-].CC[N+]1=C(C)C=CC=C1\C=C\NC1=CC=C(Br)C=N1 FEYNAYMVKUTMFN-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229930182497 flavan-3-ol Natural products 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003662 hair growth rate Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- UWKUITBHNDJYCO-UHFFFAOYSA-M sodium 2-(aminomethyl)tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCC(CN)C([O-])=O UWKUITBHNDJYCO-UHFFFAOYSA-M 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CGFPNELNAZZYQL-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CGFPNELNAZZYQL-RXSVEWSESA-N 0.000 description 1
- OZXPGWNBRLSTAI-RBBKRZOGSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-3-octadecoxy-2h-furan-5-one Chemical compound CCCCCCCCCCCCCCCCCCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO OZXPGWNBRLSTAI-RBBKRZOGSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- NRZZLYODXDSLEK-UHFFFAOYSA-N (6-ethoxy-6-oxohexyl) 3,5-diacetamido-2,4,6-triiodobenzoate Chemical compound CCOC(=O)CCCCCOC(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I NRZZLYODXDSLEK-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BVYZDBLMCKSKAT-UHFFFAOYSA-N 2,2,3,3-tetrahexyldecanoic acid Chemical compound CCCCCCCC(CCCCCC)(CCCCCC)C(CCCCCC)(CCCCCC)C(O)=O BVYZDBLMCKSKAT-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000156724 Antirhea Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241001504466 Carduelis Species 0.000 description 1
- 241001655736 Catalpa bignonioides Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KIENGQUGHPTFGC-JLAZNSOCSA-N L-ascorbic acid 6-phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O KIENGQUGHPTFGC-JLAZNSOCSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000016677 Lespedeza bicolor Nutrition 0.000 description 1
- 240000000604 Lespedeza bicolor Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- XJCCHWKNFMUJFE-CGQAXDJHSA-N Maltotriitol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 XJCCHWKNFMUJFE-CGQAXDJHSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- FCKLFGKATYPJPG-SSTBVEFVSA-N Oxendolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 FCKLFGKATYPJPG-SSTBVEFVSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 235000010913 Picrasma quassioides Nutrition 0.000 description 1
- 240000004659 Picrasma quassioides Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000847801 Simaba cedron Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- ZTLBKEBOAKWETD-UHFFFAOYSA-N [Na].[N+](=O)([O-])C1=C(C(=CC=C1)OC)O Chemical compound [Na].[N+](=O)([O-])C1=C(C(=CC=C1)OC)O ZTLBKEBOAKWETD-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- KQZNFGJQTPAURD-NBWQQBAWSA-N ascorbyl dipalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)C(O)=C1O KQZNFGJQTPAURD-NBWQQBAWSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 229930015036 aurone Natural products 0.000 description 1
- 150000001530 aurones Chemical class 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229950004210 cromakalim Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 150000005835 flavan-3,4-diols Chemical class 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- UTTVXKGNTWZECK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine oxide Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)[O-] UTTVXKGNTWZECK-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229950006827 oxendolone Drugs 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 208000005814 piedra Diseases 0.000 description 1
- 229960002310 pinacidil Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
正常ヒト頭髪毛乳頭細胞の増殖に及ぼすL−アスコルビン酸類、ヘスペリジン、ルチン、リボフラビン又は感光素301号の影響を調べる実験を、ヒト毛乳頭細胞を使用して、以下のようにしておこなった。
正常ヒト頭髪毛乳頭細胞(東洋紡績株式会社販売、商品名「正常ヒト頭髪毛乳頭細胞」)(以下、「ヒト毛乳頭細胞」と略記する場合がある。)を、1容積%ウシ胎児血清(以下、「FCS」と略記する。)を含むヒト毛乳頭細胞培養培地(東洋紡績株式会社販売、商品名「毛乳頭細胞増殖培地」、「正常ヒト頭髪毛乳頭細胞」に同梱)を用いて、37℃、5容積%CO2の条件で、75cm2のカルチャーフラスコ(コーニング社販売、商品名「75cm2カルチャーフラスコ」)で培養した。この細胞(継代数4)を、0.05%トリプシン含有リン酸緩衝生理食塩水を用いて回収し、1容積%FCSを添加したダルベッコウのMEM培地(ギブコ社販売、以下、「DMEM」と略記する。)に再懸濁し、96ウエルのマイクロプレート(岩城硝子株式会社販売、商品名「コラーゲンタイプIコート96ウエルプレート」)に、1.5×103細胞/50μl/ウエルで播種し、以下の試験に使用した。
L−アスコルビン酸(以下、「AsA」と略記する場合がある。)、L−アスコルビン酸2−グルコシド(株式会社林原生物化学研究所販売、商品名「AA2G」、純度98%以上)(以下、「AA−2G」と略記する場合がある。)、ヘスペリジン(シグマ社販売、商品名「ヘスペリジン」)、ルチン(シグマ社販売、商品名「ルチン」)、リボフラビン(シグマ社販売、商品名「リボフラビン」)及び感光素301号(株式会社林原生物化学研究所販売、商品名「タカナール」、純度99%以上)を試験試薬として使用し、その何れか1種を、最終濃度が、表1又は表2に記載の濃度となるように、1容積%のFCS添加DMEM培地に添加し試験液を調製した。これら何れかの試験液を、先に調製したヒト毛乳頭細胞培養96ウエルプレートに50μl/ウエルで添加し、5容積%CO2、37℃の条件で、4日間培養後、MTT法を用いてヒト毛乳頭細胞の増殖率を求め、その結果を表1又は表2に示す。なお、ヒト毛乳頭細胞の増殖率(%)は、1容積%FCS添加DMEMに、塩基性線維芽細胞増殖因子(以下、「bFGF」と略記する場合がある。)を最終濃度10ng/mlになるように加えて培養したヒト毛乳頭細胞を陽性対照とし、1容積%FCS添加DMEMのみで培養したヒト毛乳頭細胞を陰性対照として用い、450nmの吸光度を測定して、次式により求めた。増殖率(%)={(試料の吸光度−陰性対照の吸光度)÷(陽性対照の吸光度−陰性対照の吸光度)}×100
ヒト毛乳頭細胞の増殖に及ぼすグルコシルヘスペリジン、グルコシルルチン、グルコシルナリンジン、マルトース、α,α−トレハロース、マルチトール、α−マルトシルα,α−トレハロース、環状ニゲロシルニゲロース或いは環状マルトシルマルトースの影響を調べる実験を、以下のようにしておこなった。すなわち、グルコシルヘスペリジン(株式会社林原生物化学研究所販売、試薬級、純度98%以上)、グルコシルルチン(株式会社林原生物化学研究所製造、純度98%以上)、グルコシルナリンジン(株式会社林原生物化学研究所製造、純度98%以上)、マルトース(株式会社林原生物化学研究所販売、試薬級、純度99%以上)、α,α−トレハロース(株式会社林原生物化学研究所販売、化粧品用、純度99%以上)、マルチトール(株式会社林原生物化学研究所販売、試薬級、純度99%以上)α−マルトシルα,α−トレハロース(株式会社林原生物化学研究所製造、純度98%以上)、環状ニゲロシルニゲロース(株式会社林原生物化学研究所製造、純度98%以上)、環状マルトシルマルトース(株式会社林原生物化学研究所製造、純度98%以上)を試験試薬として使用し、その何れか1種を、最終濃度が、表3或いは表4に記載の濃度となるように、1容積%のFCS添加DMEM培地に添加し試験液を調製した。これら何れかの試験液を、実験1と同様に調製したヒト毛乳頭細胞培養96ウエルプレートに50μl/ウエルで添加し、5容積%CO2、37℃の条件で、4日間培養後、実験1と同じ方法で、MTT法を用いてヒト毛乳頭細胞の増殖率(%)を求め、グルコシルヘスペリジン、グルコシルルチン或いはグルコシルナリンジンを添加した場合の結果を表3に、マルトース、α,α−トレハロース、マルチトール、α−マルトシルα,α−トレハロース、環状ニゲロシルニゲロース、或いは、環状マルトシルマルトースを添加した場合の結果を表4に示す。
実験1及び実験2から、L−アスコルビン酸2−グルコシドや非還元性糖類と、感光素301号、ヘスペリジン、グルコシルルチン或いはリボフラビンとは、ヒト毛乳頭増殖の作用機作が異なることが判明したので、L−アスコルビン酸2−グルコシドの毛乳頭細胞増殖促進作用に及ぼす感光素301号、ヘスペリジン、グルコシルルチン、リボフラビン、α,α−トレハロース或いは環状ニゲロシルニゲロースの影響を調べる実験を、以下のようにしておこなった。すなわち、L−アスコルビン酸2−グルコシド(株式会社林原生物化学研究所販売、商品名「AA2G」、純度98%以上)、感光素301号(株式会社林原生物化学研究所販売、商品名「タカナール」)、ヘスペリジン(シグマ社販売、商品名「ヘスペリジン」)、リボフラビン(シグマ社販売、商品名「リボフラビン」)、グルコシルルチン(株式会社林原生物化学研究所製造、純度98%以上)、α,α−トレハロース(林原生物化学研究所販売、試薬級、純度99%以上)及び環状ニゲロシルニゲロース(株式会社林原生物化学研究所製造、純度98%以上)を試験薬剤として使用し、最終濃度が、表5に記載の濃度となるように、1容積%のFCSを含むDMEM培地に添加し試験液を調製した。これら何れかの試験液を、実験1と同じ方法で調製したヒト毛乳頭細胞培養96ウエルプレートに50μl/ウエルで添加し、5容積%CO2、37℃の条件で、4日間培養後、MTT法を用いて実験1と同じ方法で、各試験液で培養したヒト毛乳頭細胞の増殖率を求めた。この増殖率を使用して、Chou J. H.(「Synergism and antagonism in chemotherapy」,223−241,1991参照)の理論に基づき、L−アスコルビン酸2−グルコシドと他の試験試薬の二剤を併用した時のL−アスコルビン酸2−グルコシドの投与量の併用効果指数(Combination Index、以下「CI」と略記する。)を、CI計算用ソフト(カルックシン(CalcuSyn)、バイオソフト(BIOSOFT)社(英国)販売)で計算し、その結果を表5に示す。また、CIに基づく、二剤併用時の相乗効果の程度は、表6に示す当該計算ソフトに添付されたマニュアルに記載の判定基準に基づき判定し、併せて、表5に示す。
毛周期に及ぼすL−アスコルビン酸2−グルコシド、グルコシルヘスペリジン、グルコシルルチン、グルコシルリボフラビン、グルコシルナリンジン、感光素301号、或いはα,α−トレハロースの糖質誘導体の影響を調べる試験を以下のように行った。すなわち、L−アスコルビン酸2−グルコシド(株式会社林原生物化学研究所販売、商品名「AA2G」、純度98%以上)、グルコシルヘスペリジン(株式会社林原生物化学研究所販売、試薬級、純度98%以上)、グルコシルルチン(株式会社林原生物化学研究所製造、純度98%以上)、グルコシルリボフラビン(株式会社林原生物化学研究所製造、純度98%以上)、グルコシルナリンジン(株式会社林原生物化学研究所製造、純度98%以上)及び感光素301号(株式会社林原生物化学研究所販売、商品名「タカナール」、純度98%以上)、α,α−トレハロースの糖質誘導体含有糖質(株式会社林原生物化学研究所販売、商品名「トルナーレ」、α−マルトシルα,α−トレハロースを無水物換算で約53%含有)を試験試薬として使用した。L−アスコルビン酸2−グルコシド1%、クエン酸1%、クエン酸ナトリウム1%、70%エタノール90%、硬化ヒマシ油エチレンオキシド(40モル付加物)1%からなる基本処方に、表7に示す前記試験試薬の何れか1種を、表7に示す量添加し、適量のイオン交換水を加えて全量を100%として、常法により試験用の育毛料No1乃至育毛料No6を調製した。また、基本処方に適量のイオン交換水を加えて全量を100%とした育毛料No7及び、陰性対照として、基本処方からL−アスコルビン酸2−グルコシドを除いた処方に適量のイオン交換水を加えて、全量を100%として育毛料No8を調製した。なお、α,α−トレハロースの糖質誘導体含有糖質は、α−マルトシルα,α−トレハロースの配合割合が0.5%となるように添加した。
試験用の育毛料No1乃至育毛料No7及び陰性対照(育毛料No8)の育毛料を用いてこれらの育毛料の毛周期に及ぼす影響を調べるために、ヒトに対して、以下の方法で試験を実施した。すなわち、育毛料No1乃至育毛料No7或いは陰性対照(育毛料No8)の何れか1種を、男性型脱毛に悩む男性10名(合計80名)を被験者として、1日に朝晩2回、6ヶ月間使用を続けてもらった。育毛料の有効性評価は、塗布直前及び塗布終了直後に、被験者1名につき脱毛部位に残存している毛髪を、無作為に30本抜毛し、毛根を顕微鏡で観察した。毛根の形態により、休止期毛根数を計数し、休止期毛根の割合を求め、休止期毛根の割合が、試験育毛料塗布前に比して20%以上減少、20%未満減少乃至20%未満増加、20%以上増加の3群に分けて、その人数を表7に示す。また、各試験育毛料を塗布した被験者に占める、休止期毛根の割合が、塗布前に比して20%以上減少した被験者の割合(%)を求め、下記の判定基準に基づき、毛周期の回転に及ぼす効果を評価して、結果を表7に示す。なお、試験を通じて、安全性に関する問題は見られなかった。
休止期毛根の割合が育毛料使用前に比して20%以上減少した被験者が、40%以上である場合を「有効」、20%以上40%未満である場合を「やや有効」、20%未満である2合を「無効」とした。
自毛植毛した際の毛乳頭細胞の増殖に及ぼすL−アスコルビン酸2−グルコシド、糖転移ヘスペリジン、糖転移ルチン、糖転移リボフラビン、感光素301号、α,α−トレハロース或いはα−マルトシルα,α−トレハロースの影響を調べる実験を自毛移植の際の移植毛を使用して、以下のようにしておこなった。
自毛植毛を希望する脱毛症の男性80名を、無作為に10名ずつ8つのグループに分けた。各自の後頭部の健康毛の部位から、常法により、毛髪のはえた頭皮を、外科的に採取した。採取した頭皮を、抗菌剤を含む生理食塩水で洗浄後、試験試薬として、実験1で使用したものと同じL−アスコルビン酸2−グルコシド、及び、実験2で使用したものと同じグルコシルヘスペリジン、グルコシルルチン、グルコシルリボフラビン、感光素301号、α,α−トレハロース或いはα−マルトシルα,α−トレハロースの何れかを、生理食塩水に添加して、表8に示す濃度となるように調製した処理液に2時間浸漬し、その浸漬期間中に、処理液中で、個々の毛髪乃至休止期の移植毛を、移植用に切り分けた。対照として生理食塩水のみを使用した処理液で、移植用の毛髪乃至休止期の移植毛を調製した。
処理液に2時間浸漬した移植毛を、生理食塩水に移し、常法により、脱毛部位の頭皮に移植した。移植終了後、移植部位をデジタルカメラで撮影し、約100本の毛髪を移植した部位を特定して、その範囲に移植した移植毛の本数を正確にカウントした。移植60日後に、前に撮影したデジタルカメラの映像を基に、移植時にその移植毛の本数をカウントした部位について、移植毛の数をカウントし、移植時の本数で除し、100倍して、移植毛の着生率(%)を求め、その結果を表8に示す。
実験5から、L−アスコルビン酸2−グルコシド、感光素301号、グルコシルヘスペリジン、グルコシルルチン、グルコシルリボフラビン、α,α−トレハロース、或いは、α−マルトシルα,α−トレハロースは、自毛移植時の移植毛の着生率を向上させる作用があることが判明したので、L−アスコルビン酸2−グルコシドの移植毛の着生に及ぼす感光素301号、グルコシルヘスペリジン、グルコシルルチン、グルコシルリボフラビン、α,α−トレハロース、或いは、α−マルトシルα,α−トレハロースの影響を調べる実験を、以下のようにしておこなった。すなわち、実験5で使用したものと同じ試験薬剤を使用し、最終濃度が、L−アスコルビン酸2−グルコシドは、実験5の10分の1の1mMとし、L−アスコルビン酸2−グルコシド以外は、実験5と同じ濃度として、表9に示す濃度となるように、処理液を調製した。これらの処理液を使用して、実験5と同一の方法、条件で、各処理液につき10名の脱毛症の男性に自毛植毛を実施した。植毛後60日目に、実験5と同じ方法で移植毛の本数をカウントして、着生率を求めて、L−アスコルビン酸2−グルコシドと感光素301号、グルコシルヘスペリジン、グルコシルグルコシルルチン、グルコシルリボフラビン、α,α−トレハロース、或いは、α−マルトシルα,α−トレハロースとの併用の効果を調べて、その結果を表9に示した。
以下の成分を以下の配合で均一に混合して、毛乳頭細胞増殖促進剤を調製した。
販売、商品名「トレハ」) 69
L−アスコルビン酸2−グルコシド(株式会社林原
生物化学研究所販売、商品名「AA2G」) 28
グルコシルヘスペリジン(株式会社林原生物化学研
究所販売、商品名「林原ヘスペリジンS」) 1
グルコシルルチン(株式会社林原商事販売、商品名
「αGルチン」) 1
グルコシルリボフラビン(株式会社林原生物化学研
究所製造) 1
以下の成分を以下の配合で均一に混合して、毛乳頭細胞増殖促進剤を調製した。
株式会社林原生物化学研究所販売、商品名「トルナ
ーレ」) 75
L−アスコルビン酸2−グルコシド(株式会社林原
生物化学研究所販売、商品名「AA2G」) 24
グルコシルヘスペリジン(株式会社林原生物化学研
究所販売、商品名「林原ヘスペリジンS」) 0.5
グルコシルリボフラビン(株式会社林原生物化学研
究所製造) 0.3
感光素301号(株式会社林原生物化学研究所販売、
商品名「タカナール」) 0.2
以下の成分を以下の配合で均一に混合して、液状の毛乳頭細胞増殖促進剤を調製した。
L−アスコルビン酸2−グルコシド 2
クエン酸 0.01
クエン酸ナトリウム 0.1
グルコシルヘスペリジン 0.5
ステアリルジメチルアミンオキシド 0.5
硬化ヒマシ油エチレンオキシド(40モル)付加物 1
α,α−トレハロースの糖質誘導体含有糖質(株式会
社林原生物化学研究所販売、商品名「トルナーレ) 1
95%エタノール 54
イオン交換水 残量
以下の成分を以下の配合で均一に混合して、液状の毛乳頭細胞増殖促進剤を調製した。
L−アスコルビン酸2−グルコシド 2
クエン酸 0.01
クエン酸ナトリウム 0.1
グルコシルヘスペリジン 0.5
N−ヤシラウリル−β−アミノプロピオン酸ソーダ 0.2
ドデシルベンゼンスルホン酸ナトリウム 0.5
硬化ヒマシ油エチレンオキシド(40モル)付加物 1
藍エキス(株式会社林原生物化学研究所販売、商品名
「藍ルーロス」) 1
95%エタノール 54
イオン交換水 残量
下記配合に基づき、A相を60℃で加熱溶解し、これに溶解したB相を加え、次にC相を添加し混合した。これにD相を徐々に添加し分散させ、ジェル状の毛乳頭細胞増殖促進剤を調製した。
(A相)
硬化ヒマシ油エチレンオキシド(60モル)付加物 2
グリセリン 10
ジプロピレングリコール 10
1,3−ブチレングリコール 5
ポリエチレングリコール1500 5
ペンチレングリコール 3.5
(B相)
カルボキシビニルポリマー1%水溶液 30
ヘキサメタリン酸ソーダ 0.03
イオン交換水 8.35
(C相)
水酸化カリウム 0.12
イオン交換水 5
(D相)
L−アスコルビン酸2−グルコシド 2
水酸化カリウム 3
グルコシルリボフラビン 0.05
イオン交換水 15.95
下記配合に基づき、A相、B相をそれぞれ加熱溶解して混合し、ホモミキサーで乳化してクリーム状の毛乳頭細胞増殖促進剤を調製した。
(A相)
流動パラフィン 5
セトステアリルアルコール 5.5
グリセリルモノステアレート 3
EO(20モル)−2−オクチルドデシルエーテル 3
プロピルパラベン 0.3
香料 0.1
(B相)
L−アスコルビン酸2−グルコシド 2
クエン酸 0.01
クエン酸ナトリウム 0.1
感光素301号 0.005
グリセリン 7
サイクリックマルトシルマルトース(株式会社林原生
物化学研究所製造) 1
ジプロピレングリコール 20
ポリエチレングリコール4000 5
ドデシル硫酸ナトリウム 0.1
ヘキサメタリン酸ソーダ 0.005
イオン交換水 残量
下記配合処方に基づき、95%エタノールに適量のイオン交換水を加え、これに、実施例2の方法で調製した毛乳頭細胞増殖促進剤、硬化ヒマシ油エチレンオキシド(40モル)付加物及びポリオキシエチレンラウリルアミンオキシド、ジメチルラウリルアミンオキシドを加えた後、攪拌して、液状の毛乳頭細胞増殖促進剤を得た。
実施例2の方法で調製した毛乳頭細胞増殖促進剤 1
ポリオキシエチレンラウリルアミンオキシド 0.1
ジメチルラウリルアミンオキシド 1
硬化ヒマシ油エチレンオキシド(40モル)付加物 1
マルチトール 0.5
95%エタノール 54
香料 適量
イオン交換水 残量
下記配合処方に基づき、液状の毛乳頭細胞増殖促進剤を調製した。
L−アスコルビン酸2−グルコシド 2
クエン酸 0.01
クエン酸ナトリウム 0.1
グルコシルルチン 0.5
グルコシルナリンジン(株式会社林原生物化学研究所製造) 0.2
感光素301号 0.001
N−ヤシラウリル−β−アミノプロピオン酸ソーダ 0.2
ドデシルベンゼンスルホン酸ナトリウム 0.5
硬化ヒマシ油エチレンオキシド(40モル)付加物 1
サイクリックニゲロシルニゲロース 0.1
95%エタノール 54
イオン交換水 残量
以下の成分を以下の配合で均一に混合して、粉末状の毛乳頭細胞増殖促進剤を調製した。
販売、商品名「トレハ」) 65.5
L−アスコルビン酸2−グルコシド(株式会社林原
商事販売、商品名「アスコフレッシュ」) 15
キトサン 15
糖転移ヘスペリジン(株式会社林原商事販売、商品
名「林原グルコシルヘスペリジンS」) 2
グルコシルリボフラビン 1
アデノシンモノフォスフェイト 1
コエンザイムQ10 0.5
粉末マルチトール 35
実施例1の方法で調製した毛乳頭細胞増殖促進剤 15
粉末卵黄 19
脱脂粉乳 20
塩化ナトリウム 4.5
塩化カリウム 1.85
硫酸マグネシウム 4
チアミン 0.01
ビタミンEアセテート 0.6
ニコチン酸アミド 0.04
上記配合組成からなる配合物を調製した。この配合物25質量部を精製水150質量部に均一に分散・溶解させ、200gずつ褐色ガラス瓶に封入した。
Claims (1)
- 自毛植毛の際に、移植用の毛髪の浸漬処理に用いるための、L−アスコルビン酸2−グルコシドを有効成分として含有する、移植毛の頭皮への着生率向上剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007555917A JP5635226B2 (ja) | 2006-01-24 | 2007-01-19 | 毛乳頭細胞増殖促進剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006014568 | 2006-01-24 | ||
JP2006014568 | 2006-01-24 | ||
JP2007555917A JP5635226B2 (ja) | 2006-01-24 | 2007-01-19 | 毛乳頭細胞増殖促進剤 |
PCT/JP2007/050811 WO2007086327A1 (ja) | 2006-01-24 | 2007-01-19 | 毛乳頭細胞増殖促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007086327A1 JPWO2007086327A1 (ja) | 2009-06-18 |
JP5635226B2 true JP5635226B2 (ja) | 2014-12-03 |
Family
ID=38309122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007555917A Expired - Fee Related JP5635226B2 (ja) | 2006-01-24 | 2007-01-19 | 毛乳頭細胞増殖促進剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5635226B2 (ja) |
WO (1) | WO2007086327A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5551582B2 (ja) * | 2008-03-17 | 2014-07-16 | 株式会社林原 | 皮膚外用剤 |
JP2010077123A (ja) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | メイラード反応阻害剤 |
WO2010029913A1 (ja) * | 2008-09-11 | 2010-03-18 | 株式会社林原生物化学研究所 | 気力改善剤 |
MX2012002696A (es) | 2009-09-03 | 2012-08-15 | Hayashibara Biochem Lab | Composicion particulada que contiene ácido 2-0-alfa-d-glucosil-l-a scórbico anhidro cristalino, procedimiento para la producción de la misma, y sus usos. |
WO2012033218A1 (ja) | 2010-09-07 | 2012-03-15 | 株式会社林原生物化学研究所 | 2−O−α−D−グルコシル−L−アスコルビン酸含水結晶及び2−O−α−D−グルコシル−L−アスコルビン酸含水結晶含有粉末とそれらの製造方法並びに用途 |
MY165639A (en) | 2011-03-07 | 2018-04-18 | Hayashibara Co | A process for producing a particulate composition comprising anhydrous crystalline 2-o-alpha-d-glucosyl-l-ascorbic |
JP5775212B2 (ja) * | 2011-04-26 | 2015-09-09 | ヤング リー,ヒー | 毛髪移植素材 |
JP5921868B2 (ja) * | 2011-12-14 | 2016-05-24 | 花王株式会社 | 育毛料組成物の製造方法 |
US10543159B2 (en) | 2014-11-20 | 2020-01-28 | Ezaki Glico Co., Ltd. | Hair papilla cell activator |
KR102466224B1 (ko) * | 2015-12-02 | 2022-11-10 | 킨지루시 가부시키 가이샤 | 육모ㆍ발모 촉진제 |
JP2018203681A (ja) * | 2017-06-07 | 2018-12-27 | 日本メナード化粧品株式会社 | くせ毛改善剤 |
JP2019085345A (ja) * | 2017-11-02 | 2019-06-06 | ロート製薬株式会社 | 発毛因子産生促進剤及び/又は細胞接着分子産生促進剤 |
JP2020186218A (ja) * | 2019-05-17 | 2020-11-19 | ロート製薬株式会社 | 発毛因子産生促進剤及び/又は毛再生剤及び/又は脱毛抑制剤 |
CN113425636B (zh) * | 2021-05-21 | 2023-01-31 | 广州德谷个人护理用品有限公司 | 一种茶麸黄酮的制备方法及其在防脱发产品中的应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734828A (en) * | 1970-03-31 | 1973-05-22 | Hayashibara Co | Process for the separation and purification of riboflavinyl glycosides |
JPH0377809A (ja) * | 1989-08-21 | 1991-04-03 | Arusoa Sogo Kenkyusho:Kk | 養毛料 |
JPH0446112A (ja) * | 1990-06-11 | 1992-02-17 | Hayashibara Biochem Lab Inc | 養毛剤 |
JPH04182415A (ja) * | 1990-11-19 | 1992-06-30 | Kaminomoto Honpo:Kk | 発毛・養毛促進剤 |
JPH072677A (ja) * | 1993-06-18 | 1995-01-06 | Toyo Seito Kk | 経口育毛剤 |
JPH08291025A (ja) * | 1995-04-25 | 1996-11-05 | Akihisa Ueda | 養毛料 |
JPH10508313A (ja) * | 1994-12-08 | 1998-08-18 | クレット−ロッホ、ローレ、マリア | 毛髪の成長、及び、選択的には皮膚並びに爪の成長を促進し、抜け毛を防止又は抑制する合成製剤 |
JP2000038340A (ja) * | 1998-05-20 | 2000-02-08 | Kumahiro Miyama | 育毛剤および食品 |
JP2002255827A (ja) * | 2001-03-01 | 2002-09-11 | Shiseido Co Ltd | 皮膚外用剤 |
WO2004071472A1 (ja) * | 2003-02-13 | 2004-08-26 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α,α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤 |
WO2004076602A1 (ja) * | 2003-02-27 | 2004-09-10 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 脂質膜を構成している脂質の分解抑制方法及びその用途 |
WO2005087182A1 (ja) * | 2004-03-17 | 2005-09-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 機能性粉体 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085788B2 (ja) * | 1987-10-08 | 1996-01-24 | 花王株式会社 | 5α−リダクターゼ阻害剤 |
JP2791673B2 (ja) * | 1989-01-23 | 1998-08-27 | 花王株式会社 | 5α―リダクターゼ阻害剤 |
JPH03287516A (ja) * | 1989-07-17 | 1991-12-18 | Daiko Sangyo:Kk | 発毛剤 |
JPH04182414A (ja) * | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 頭髪化粧料 |
JPH062655B2 (ja) * | 1991-03-04 | 1994-01-12 | 完夫 塚田 | 養毛・育毛剤 |
JPH05194204A (ja) * | 1992-01-20 | 1993-08-03 | Lion Corp | 抗男性ホルモン剤 |
JP3202135B2 (ja) * | 1994-08-10 | 2001-08-27 | カネボウ株式会社 | 頭髪化粧料 |
JP2971749B2 (ja) * | 1994-09-06 | 1999-11-08 | 呉羽化学工業株式会社 | 毛母細胞活性化剤および毛母細胞活性化方法 |
JP3302535B2 (ja) * | 1995-08-17 | 2002-07-15 | キッコーマン株式会社 | 上皮細胞増殖促進剤 |
JPH10279438A (ja) * | 1997-03-31 | 1998-10-20 | Kureha Chem Ind Co Ltd | 発毛育毛組成物 |
JP2000026269A (ja) * | 1998-07-13 | 2000-01-25 | Kanebo Ltd | 化粧料 |
JP4173667B2 (ja) * | 2001-02-28 | 2008-10-29 | 北海道三井化学株式会社 | アンドロゲン受容体作用阻害剤 |
JP2004244350A (ja) * | 2003-02-13 | 2004-09-02 | Mibelle Ag Cosmetics | スキンケアおよびヘアケア用化粧品 |
JP2007008900A (ja) * | 2005-07-04 | 2007-01-18 | Bio Yakuhin Kk | ビフラボン類を有効成分とする育毛剤 |
JP2007022957A (ja) * | 2005-07-15 | 2007-02-01 | Tsumura & Co | TGF−β受容体拮抗剤 |
-
2007
- 2007-01-19 JP JP2007555917A patent/JP5635226B2/ja not_active Expired - Fee Related
- 2007-01-19 WO PCT/JP2007/050811 patent/WO2007086327A1/ja active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734828A (en) * | 1970-03-31 | 1973-05-22 | Hayashibara Co | Process for the separation and purification of riboflavinyl glycosides |
JPH0377809A (ja) * | 1989-08-21 | 1991-04-03 | Arusoa Sogo Kenkyusho:Kk | 養毛料 |
JPH0446112A (ja) * | 1990-06-11 | 1992-02-17 | Hayashibara Biochem Lab Inc | 養毛剤 |
JPH04182415A (ja) * | 1990-11-19 | 1992-06-30 | Kaminomoto Honpo:Kk | 発毛・養毛促進剤 |
JPH072677A (ja) * | 1993-06-18 | 1995-01-06 | Toyo Seito Kk | 経口育毛剤 |
JPH10508313A (ja) * | 1994-12-08 | 1998-08-18 | クレット−ロッホ、ローレ、マリア | 毛髪の成長、及び、選択的には皮膚並びに爪の成長を促進し、抜け毛を防止又は抑制する合成製剤 |
JPH08291025A (ja) * | 1995-04-25 | 1996-11-05 | Akihisa Ueda | 養毛料 |
JP2000038340A (ja) * | 1998-05-20 | 2000-02-08 | Kumahiro Miyama | 育毛剤および食品 |
JP2002255827A (ja) * | 2001-03-01 | 2002-09-11 | Shiseido Co Ltd | 皮膚外用剤 |
WO2004071472A1 (ja) * | 2003-02-13 | 2004-08-26 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α,α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤 |
WO2004076602A1 (ja) * | 2003-02-27 | 2004-09-10 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 脂質膜を構成している脂質の分解抑制方法及びその用途 |
WO2005087182A1 (ja) * | 2004-03-17 | 2005-09-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 機能性粉体 |
Non-Patent Citations (5)
Title |
---|
CSNC200801353020; フレグランスジャーナル,2002,Vol.30,No.2,pp.72-75 * |
JPN6012054818; 感光色素,1988,Vol.90,pp.13-25 * |
JPN6012054819; 感光色素,1988,Vol.90,pp.1-12 * |
JPN6012054820; J. Soc. Cosmet. Chem. Jpn., 1993,Vol.26, No.4,pp.247-253 * |
JPN6012054821; フレグランスジャーナル,2002,Vol.30,No.2,pp.72-75 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007086327A1 (ja) | 2009-06-18 |
WO2007086327A1 (ja) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5635226B2 (ja) | 毛乳頭細胞増殖促進剤 | |
EP3300731A1 (en) | Hair restoration/growth stimulating agent | |
JP5479891B2 (ja) | 新規ローヤルゼリー分画物とその製造方法並びに用途 | |
JP2011102270A (ja) | 抗糖化剤 | |
JPWO2007018124A1 (ja) | コラーゲン産生増強剤とその用途 | |
JP6695809B2 (ja) | 毛乳頭細胞活性化剤 | |
JP2005306831A (ja) | 皮膚外用剤 | |
US9636289B2 (en) | Composition for preventing or treating hair loss or promoting hair growth comprising secoiridoid glucoside derivatives | |
EP2238971B1 (en) | Composition for external application | |
JP2008088075A (ja) | プロフィラグリン/フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮/角層正常化用皮膚外用剤、プロフィラグリン及び/又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
US10617622B2 (en) | Hair restoration and/or hair growth promoting composition containing soyasaponin | |
KR20140056990A (ko) | 바이칼린을 유효성분으로 포함하는 탈모 예방 또는 치료, 또는 발모 촉진용 조성물 | |
JP7135106B2 (ja) | 頭皮頭髪用組成物 | |
KR102149957B1 (ko) | 진토닌을 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
JP2011126814A (ja) | コラーゲン産生促進剤、ヒアルロン酸産生促進剤、並びにコラーゲン産生促進およびヒアルロン酸産生促進剤 | |
KR102386651B1 (ko) | 티플락스티닌을 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물 | |
WO2023191015A1 (ja) | コラーゲン産生促進剤、化粧料組成物又は皮膚外用剤、及び経口投与剤 | |
GB2572322A (en) | A hair treatment composition | |
JP5313524B2 (ja) | 抗炎症剤及び抗炎症用皮膚外用剤 | |
WO2023191016A1 (ja) | フィブリリン産生促進剤、化粧料組成物又は皮膚外用剤、経口投与剤、及びエラスチン線維産生促進剤 | |
KR20170099674A (ko) | 피부 개선용 조성물 | |
JP2004359554A (ja) | 老化防止剤及び皮膚外用剤 | |
KR20230102912A (ko) | 탈모방지 또는 발모촉진용 조성물 | |
US20220347256A1 (en) | Composition for promoting hair growth, and alleviating and treating hair loss including substance p | |
JP2003300853A (ja) | 皮膚外用剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091221 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20121210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140812 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141014 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141016 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5635226 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |